Dr Kundu is a co-founder and the Managing Director at Premas Biotech . He holds a Ph . D . in Biomedical Engineering from the Indian Institute of Technology-Bombay , and has interests in protein engineering , bioprocess development , lean transformation , and emerging technologies . Dr Kundu began his career at Bio-Rad ( India , Asia-Pacific ), before moving to Ranbaxy ( India ) and then co-founded Premas in 2006 .
At Premas , Dr Kundu has managed mutligroup specialties , including manufacturing , marketing and business development , with a keen understanding of the bio-market in India and USA . Apart from his other business interests , he is most interested in process efficiency enhancement , and has been very actively involved and implemented " Lean Management " or the " Toyota production Process " at Premas Biotech , one of the first company in India for the biology sector , along with electronic information acquisition and documentation . This provides entire bandwidth of traceability , information management and process deliveries .
Under Dr Kundu ’ s stewardship , Premas Biotech has partnered with global companies on path-breaking technologies , such as their partnership with Oramed Inc ., as only manufacturer of the proteins required for Oral Insulin , which has successfully cleared Phase IIb trials in the US . In the past 15 years , Premas Biotech has worked on more than 650 proteins for the top 20 pharma and biotech organizations across the world .
Recently Dr Kundu and his teammates successfully identified three major antigens as a recombinant novel corona virus vaccine candidate to developing a triple antigen vaccine . Unlike single-protein vaccines currently under trials across the world , Preamps Biotech has adopted a three-pronged approach to develop multi-subunit vaccine , using recombinantly expressed antigens Spike ( S ), Envelope ( E ), and Membrane ( M ) proteins in multiple formats , which it hopes will provide a good chance of immunity against COVID-19 .
Current Position : Co founder & Managing Director , Premas Biotech
Impact : In a first kind of approach , implemented " Lean Management " or the " Toyota production Process " for the biology sector , along with electronic information acquisition and documentation
Alma Mater : IIT Bombay
In his more than 20 years of professional experience , Dr Kundu has published more than 22 publications and ten patents , as well as speaking engagements at international conferences . He is an active member of the Confederation of Indian Industries ( CII ) - Biotech Group , various institutions , and self-help groups on education , healthcare , and innovations .
Dr Kundu belives that when lab data becomes information that is when it becomes useful . “ That is where smart labs are going to make a difference , because we know our data is stuck as information . It ’ s not accessible . It ’ s not democratic . The minute you digitize it , your democratizing data , which means , is now accessible ,” he says .
BioTech
BIOVOICENEWS . COM 45